$INNV PR mutiple support 'bottom' Bot $0.2549 l
Post# of 63691
Posted On: 11/29/2016 7:35:47 AM
$INNV PR mutiple support 'bottom'
Bot $0.2549 last week
flag support
multi-bagger corrected
OTC
Website
Signs $2 Million a Year Exclusive License and Distribution Agreement
with J&H Co. LTD for Zestra® for Female Sexual Arousal in South Korea
Agreement Currently Expected to Add $20 million in Revenues Over the Life of the Agreement
10-Q 11/15/16
O/S 106,080,636
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The companys pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.
Bot $0.2549 last week
flag support
multi-bagger corrected
OTC
Website
Signs $2 Million a Year Exclusive License and Distribution Agreement
with J&H Co. LTD for Zestra® for Female Sexual Arousal in South Korea
Agreement Currently Expected to Add $20 million in Revenues Over the Life of the Agreement
10-Q 11/15/16
O/S 106,080,636
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The companys pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.
(0)
(0)Scroll down for more posts ▼